表紙
市場調查報告書
商品編碼
1004444

神經內分泌腫瘤的全球市場:到2028年的行業趨勢和預測

Global Neuroendocrine Tumors Market - Industry Trends and Forecast to 2028

出版日期: | 出版商: Data Bridge Market Research Private Limited | 英文 418 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預計的2021-2028期間,全球神經內分泌腫瘤市場預計將以10.4%的複合年增長率增長。市場上的關鍵增長因素包括對靶向療法的需求增加以及私人癌症診斷中心和醫療機構的數量增加。

本報告調查了全球神經內分泌腫瘤市場,包括市場增長和抑制因素,機遇與挑戰,COVID-19影響,分類,執行人員,職等,類型,給藥途徑,最終用戶,我們提供諸如市場分析之類的信息按分銷渠道/地區,競爭狀況和主要公司的概況。

目錄

第1章簡介

第2章全球神經內分泌腫瘤市場:細分

  • 目標市場
  • 地理範圍
  • 考慮調查的年份
  • DBMR TRIPOD數據驗證模型
  • 與主要輿論領袖的訪談
  • 多元建模
  • 分類生命線曲線
  • DBMR市場位置網格
  • 供應商份額分析
  • 市場最終用戶覆蓋率
  • 次要材料
  • 先決條件

第3章執行摘要

第4章重要注意事項

第5章管道分析

第6章價格分析

第7章全球神經內分泌腫瘤市場:法規

  • 美國的監管程序
  • 加拿大的監管程序
  • 歐洲的監管程序
  • 中國的監管程序
  • 中東和非洲的監管程序

第8章單克隆抗體和多克隆抗體的比較分析

  • 單克隆抗體
  • 多克隆抗體

第9章市場概述

  • 生長因素
    • 神經內分泌腫瘤病例的發生率增加
    • 檢測神經內分泌腫瘤的技術進步
    • 私人診斷中心和治療提供者的數量增加
    • 目標治療方案的存在
    • 優惠兌換政策
  • 抑制因素
    • 生物標誌物和孤兒藥的高資本投資和低成本效益
    • 意識不足
    • 獲得未滿足的需求醫療資源
    • 高診斷成本
  • 市場機會
    • 增加政府主動性
    • 新療法和治療方法的發展
    • 合作吸引了市場參與者的注意
  • 挑戰
    • 與治療有關的副作用
    • 關於神經內分泌腫瘤藥物開發的嚴格政府法規

第10章全球神經內分泌腫瘤市場:COVID-19的影響

  • 對價格的影響
  • 需求的影響
  • 對供應鏈的影響
  • 戰略決策
  • 結論

第11章全球神經內分泌腫瘤市場:按分類

  • 概述
  • 功能性神經內分泌腫瘤
  • 非功能性神經內分泌腫瘤

第12章全球神經內分泌腫瘤市場:按受影響地區劃分

  • 概述
  • 胃腸道(GI)
  • 胰臟

第13章全球神經內分泌腫瘤市場:按等級

  • 概述
  • 2級(中度惡性腫瘤)
  • 3級(高度惡性腫瘤)
  • 1級(低度惡性腫瘤)

第14章全球神經內分泌腫瘤市場:按類型

  • 概述
  • 診斷
    • 驗血
    • 成像測試
    • 活檢
    • 尿液分析
    • 其他
  • 治療
    • 生長抑素類似物
    • 目標療法
    • 放射治療
    • 手術
    • 肝癌治療
    • 放射性核素標記□療法(PRRT)/LUTATHERA

第15章全球神經內分泌腫瘤市場:按管理途徑

  • 概述
  • 經口
    • 錠劑
    • 藥丸
    • 其他
  • 非經口
    • 皮下
    • 肌肉內
    • 其他

第16章全球神經內分泌腫瘤市場:按最終用戶分類

  • 概述
  • 醫院
  • 專科診所
  • 輻射中心
  • 醫療保健
  • 其他

第17章全球神經內分泌腫瘤市場:通過分銷渠道

  • 概述
  • 直接出價
  • 醫院藥房
  • 零售
  • 在線藥房
  • 其他

第18章全球神經內分泌腫瘤市場:按地區

  • 概述
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 俄羅斯
    • 西班牙
    • 瑞士
    • 荷蘭
    • 土耳其
    • 愛爾蘭
    • 波蘭
    • 奧地利
    • 挪威
    • 匈牙利
    • 立陶宛
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 馬來西亞
    • 印度尼西亞
    • 韓國
    • 新加坡
    • 菲律賓
    • 泰國
    • 越南
    • 其他
  • 南美洲
    • 巴西
    • 阿根廷
    • 秘魯
    • 其他
  • 中東和非洲
    • 南非
    • 沙特阿拉伯
    • 埃及
    • 以色列
    • 阿拉伯聯合酋長國
    • 科威特
    • 其他

第19章全球神經內分泌腫瘤市場:公司狀況

  • 企業份額分析:全球
  • 企業份額分析:北美
  • 企業份額分析:歐洲
  • 企業份額分析:亞太地區

第20章SWOT

第21章公司簡介

  • F. HOFFMANN-LA ROCHE LTD
  • BRISTOL-MYERS SQUIBB COMPANY
  • VIATRIS INC.
  • THERMO FISHER SCIENTIFIC INC
  • NOVARTIS AG
  • REGENERON PHARMACEUTICALS, INC.
  • ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG)
  • BIONANO GENOMICS
  • BIOSYNTHEMA INC.
  • CALLISTOPHARMA
  • ELI LILLY AND COMPANY
  • EXACT SCIENCES CORPORATION
  • GLAXOSMITHKLINE PLC
  • HUTCHISON CHINA MEDITECH LIMITED
  • IPSEN PHARMA
  • ILLUMINA, INC.
  • LUPIN
  • MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
  • PFIZER INC.
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

第22章調查表

第23章相關報告

目錄

Global neuroendocrine tumors market is projected to register a CAGR of 10.4% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation

Global Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI)), Grade (Grade 1 (Low-Grade Tumor, Grade 2 (Intermediate-Grade Tumor, Grade 3 (High-Grade Tumor)), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Hungary, Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Belgium, Austria, Norway, Ireland, Lithuania, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of the global neuroendocrine tumors market are:

  • The increased mandate for targeted treatment therapies
  • The rise in number of upcoming private cancer diagnostic centers and healthcare providers.

Market Players

The key market players for global neuroendocrine tumors market are listed below:

  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Viatris Inc.
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • LUPIN
  • Exact Sciences Corporation
  • Pfizer Inc.
  • Ipsen Pharma
  • Advanced Accelerator Applications (a subsidiary of Novartis AG)
  • BioSynthema Inc.
  • Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
  • Bionano Genomics
  • callistopharma
  • Illumina, Inc.
  • GlaxoSmithKline plc
  • Hutchison China MediTech Limited

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF THE GLOBAL NEUROENDOCRINE TUMORS MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 GLOBAL NEUROENDOCRINE TUMORS MARKET: SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 CLASSIFICATION LIFELINE CURVE
  • 2.8 DBMR MARKET POSITION GRID
  • 2.9 VENDOR SHARE ANALYSIS
  • 2.10 MARKET END USER COVERAGE GRID
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 PIPELINE ANALYSIS

6 PRICING ANALYSIS

7 GLOBAL NEUROENDOCRINE TUMORS MARKET: REGULATIONS

  • 7.1 REGULATORY PROCEDURE IN THE U.S.
  • 7.2 REGULATORY PROCEDURE IN CANADA
  • 7.3 REGULATORY PROCEDURE IN EUROPE
  • 7.4 REGULATORY PROCEDURE IN CHINA
  • 7.5 REGULATORY PROCEDURE IN MIDDLE EAST AND AFRICA

8 COMPARITIVE ANALYSIS BETWEEN MONOCLONAL AND POLYCLONAL ANTIBODY

  • 8.1 MONOCLONAL ANTIBODY
  • 8.2 POLYCLONAL ANTIBODY

9 MARKET OVERVIEW

  • 9.1 DRIVERS
    • 9.1.1 INCREASED INCIDENCE OF NEUROENDOCRINE TUMOR CASES
    • 9.1.2 TECHNOLOGICAL ADVANCEMENT FOR THE DETECTION OF NEUROENDOCRINE TUMORS
    • 9.1.3 GROWTH IN THE NUMBER OF PRIVATE DIAGNOSTIC CENTERS AND TREATMENT PROVIDERS
    • 9.1.4 PRESENCE OF TARGETED TREATMENT OPTIONS
    • 9.1.5 FAVORABLE REIMBURSEMENT POLICIES
  • 9.2 RESTRAINTS
    • 9.2.1 HIGH CAPITAL INVESTMENTS & LOW BENEFIT-COST RATIO FOR BIOMARKERS AND ORPHAN DRUGS
    • 9.2.2 LACK OF AWARENESS AMONG THE POPULATION
    • 9.2.3 UNMET NEEDS AND ACCESS TO MEDICAL RESOURCES IN SEVERAL REGIONS
    • 9.2.4 HIGH COST OF DIAGNOSIS
  • 9.3 OPPORTUNITIES
    • 9.3.1 INCREASED GOVERNMENT INITIATIVES
    • 9.3.2 EMERGING THERAPIES & DEVELOPMENT IN TREATMENT
    • 9.3.3 RISING COLLABORATIONS AMONG THE MARKET PLAYERS
  • 9.4 CHALLENGES
    • 9.4.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS
    • 9.4.2 STRINGENT GOVERNMENT REGULATIONS FOR THE DEVELOPMENT OF NEUROENDOCRINE TUMOR DRUGS

10 IMPACT OF COVID 19 ON GLOBAL NEUROENDOCRINE TUMORS MARKET

  • 10.1 PRICE IMPACT
  • 10.2 IMPACT OF DEMAND
  • 10.3 IMPACT ON SUPPLY CHAIN:
  • 10.4 STRATEGIC DECISIONS:
  • 10.5 CONCLUSION:

11 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION

  • 11.1 OVERVIEW
  • 11.2 NON-FUNCTIONAL NET
  • 11.3 FUNTIONAL NET

12 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY SITE

  • 12.1 OVERVIEW
  • 12.2 GASTROINTESTINAL TRACT (GI)
  • 12.3 LUNGS
  • 12.4 PANCREAS

13 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY GRADE

  • 13.1 OVERVIEW
  • 13.2 GRADE 2 (INTERMEDIATE-GRADE TUMOR)
  • 13.3 GRADE 3 (HIGH-GRADE TUMOR)
  • 13.4 GRADE 1( LOW-GRADE TUMOR)

14 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY TYPE

  • 14.1 OVERVIEW
  • 14.2 DIAGNOSIS
    • 14.2.1 BLOOD TEST
    • 14.2.2 IMAGING TEST
      • 14.2.2.1 CTSCAN
      • 14.2.2.2 MRI
      • 14.2.2.3 OTHERS
    • 14.2.3 BIOPSY
    • 14.2.4 URINE TEST
    • 14.2.5 OTHERS
  • 14.3 TREATMENT
    • 14.3.1 SOMATOSTATIN ANALOGS
      • 14.3.1.1 OCTREOTIDE
      • 14.3.1.2 LANREOTIDE
    • 14.3.2 TARGETED THERAPY
      • 14.3.2.1 EVEROLIMUS
      • 14.3.2.2 SUNITINIB
      • 14.3.2.3 OTHERS
    • 14.3.3 RADIATION THERAPY
      • 14.3.3.1 EXTERNAL-BEAM RADIATION
      • 14.3.3.2 INTERNAL-BEAM RADIATION
    • 14.3.4 SURGERY
      • 14.3.4.1 CHOLECYSTECTOMY
      • 14.3.4.2 OTHERS
    • 14.3.5 LIVER-DIRECTED TREATMENT
      • 14.3.5.1 RADIO FREQUENCY ABLATION (RFA)
      • 14.3.5.2 HEPATIC ARTERY EMBOLIZATION
      • 14.3.5.3 RADIOEMBOLIZATION
    • 14.3.6 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)/ LUTATHERA

15 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION

  • 15.1 OVERVIEW
  • 15.2 ORAL
    • 15.2.1 TABLETS
    • 15.2.2 PILLS
    • 15.2.3 OTHERS
  • 15.3 PARENTERAL
    • 15.3.1 SUBCUTANEOUS
    • 15.3.2 INTRAMUSCULAR
    • 15.3.3 OTHERS

16 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY END USER

  • 16.1 OVERVIEW
  • 16.2 HOSPITALS
  • 16.3 SPECIALITY CLINICS
  • 16.4 RADIATION CENTERS
  • 16.5 HOME HEALTHCARE
  • 16.6 OTHERS

17 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL

  • 17.1 OVERVIEW
  • 17.2 DIRECT TENDER
  • 17.3 HOSPITAL PHARMACY
  • 17.4 RETAIL SALES
  • 17.5 ONLINE PHARMACY
  • 17.6 OTHERS

18 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY GEOGRAPHY

  • 18.1 OVERVIEW
  • 18.2 NORTH AMERICA
    • 18.2.1 U.S.
    • 18.2.2 CANADA
    • 18.2.3 MEXICO
  • 18.3 EUROPE
    • 18.3.1 GERMANY
    • 18.3.2 FRANCE
    • 18.3.3 U.K.
    • 18.3.4 ITALY
    • 18.3.5 RUSSIA
    • 18.3.6 SPAIN
    • 18.3.7 SWITZERLAND
    • 18.3.8 NETHERLANDS
    • 18.3.9 TURKEY
    • 18.3.10 IRELAND
    • 18.3.11 POLAND
    • 18.3.12 AUSTRIA
    • 18.3.13 NORWAY
    • 18.3.14 HUNGARY
    • 18.3.15 LITHUANIA
    • 18.3.16 REST OF EUROPE
  • 18.4 ASIA PACIFIC
    • 18.4.1 CHINA
    • 18.4.2 JAPAN
    • 18.4.3 INDIA
    • 18.4.4 AUSTRALIA
    • 18.4.5 MALAYSIA
    • 18.4.6 INDONESIA
    • 18.4.7 SOUTH KOREA
    • 18.4.8 SINGAPORE
    • 18.4.9 PHILIPPINESS
    • 18.4.10 THAILAND
    • 18.4.11 VIETNAM
    • 18.4.12 REST OF ASIA-PACIFIC
  • 18.5 SOUTH AMERICA
    • 18.5.1 BRAZIL
    • 18.5.2 ARGENTINA
    • 18.5.3 PERU
    • 18.5.4 REST OF SOUTH AMERICA
  • 18.6 MIDDLE EAST AND AFRICA
    • 18.6.1 SOUTH AFRICA
    • 18.6.2 SAUDI ARABIA
    • 18.6.3 EGYPT
    • 18.6.4 ISRAEL
    • 18.6.5 UAE
    • 18.6.6 KUWAIT
    • 18.6.7 REST OF MIDDLE EAST AND AFRICA

19 GLOBAL NEUROENDOCRINE TUMORS MARKET: COMPANY LANDSCAPE

  • 19.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 19.3 COMPANY SHARE ANALYSIS: EUROPE
  • 19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

20 SWOT

21 COMPANY PROFILES

  • 21.1 F. HOFFMANN-LA ROCHE LTD
    • 21.1.1 COMPANY SNAPSHOT
    • 21.1.2 REVENUE ANALYSIS
    • 21.1.3 COMPANY SHARE ANALYSIS
    • 21.1.4 PRODUCT PORTFOLIO
    • 21.1.5 RECENT DEVELOPMENTS
  • 21.2 BRISTOL-MYERS SQUIBB COMPANY
    • 21.2.1 COMPANY SNAPSHOT
    • 21.2.2 REVENUE ANALYSIS
    • 21.2.3 COMPANY SHARE ANALYSIS
    • 21.2.4 PRODUCT PORTFOLIO
    • 21.2.5 RECENT DEVELOPMENTS
  • 21.3 VIATRIS INC.
    • 21.3.1 COMPANY SNAPSHOT
    • 21.3.2 COMPANY SHARE ANALYSIS
    • 21.3.3 PRODUCT PORTFOLIO
    • 21.3.4 RECENT DEVELOPMENTS
  • 21.4 THERMO FISHER SCIENTIFIC INC
    • 21.4.1 COMPANY SNAPSHOT
    • 21.4.2 REVENUE ANALYSIS
    • 21.4.3 COMPANY SHARE ANALYSIS
    • 21.4.4 PRODUCT PORTFOLIO
    • 21.4.5 RECENT DEVELOPMENTS
  • 21.5 NOVARTIS AG
    • 21.5.1 COMPANY SNAPSHOT
    • 21.5.2 REVENUE ANALYSIS
    • 21.5.3 COMPANY SHARE ANALYSIS
    • 21.5.4 PRODUCT PORTFOLIO
    • 21.5.5 RECENT DEVELOPMENTS
  • 21.6 REGENERON PHARMACEUTICALS, INC.
    • 21.6.1 COMPANY SNAPSHOT
    • 21.6.2 REVENUE ANALYSIS
    • 21.6.3 PRODUCT PORTFOLIO
    • 21.6.4 RECENT DEVELOPMENTS
  • 21.7 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG)
    • 21.7.1 COMPANY SNAPSHOT
    • 21.7.2 REVENUE ANALYSIS
    • 21.7.3 PRODUCT PORTFOLIO
    • 21.7.4 RECENT DEVELOPMENTS
  • 21.8 BIONANO GENOMICS
    • 21.8.1 COMPANY SNAPSHOT
    • 21.8.2 PRODUCT PORTFOLIO
    • 21.8.3 RECENT DEVELOPMENTS
  • 21.9 BIOSYNTHEMA INC.
    • 21.9.1 COMPANY SNAPSHOT
    • 21.9.2 PRODUCT PORTFOLIO
    • 21.9.3 RECENT DEVELOPMENTS
  • 21.10 CALLISTOPHARMA
    • 21.10.1 COMPANY SNAPSHOT
    • 21.10.2 PRODUCT PORTFOLIO
    • 21.10.3 RECENT DEVELOPMENTS
  • 21.11 ELI LILLY AND COMPANY
    • 21.11.1 COMPANY SNAPSHOT
    • 21.11.2 REVENUE ANALYSIS
    • 21.11.3 PRODUCT PORTFOLIO
    • 21.11.4 RECENT DEVELOPMENTS
  • 21.12 EXACT SCIENCES CORPORATION
    • 21.12.1 COMPANY SNAPSHOT
    • 21.12.2 REVENUE ANALYSIS
    • 21.12.3 PRODUCT PORTFOLIO
    • 21.12.4 RECENT DEVELOPMENTS
  • 21.13 GLAXOSMITHKLINE PLC
    • 21.13.1 COMPANY SNAPSHOT
    • 21.13.2 REVENUE ANALYSIS
    • 21.13.3 PRODUCT PORTFOLIO
    • 21.13.4 RECENT DEVELOPMENTS
  • 21.14 HUTCHISON CHINA MEDITECH LIMITED
    • 21.14.1 COMPANY SNAPSHOT
    • 21.14.2 REVENUE ANALYSIS
    • 21.14.3 PRODUCT PORTFOLIO
    • 21.14.4 RECENT DEVELOPMENTS
  • 21.15 IPSEN PHARMA
    • 21.15.1 COMPANY SNAPSHOT
    • 21.15.2 REVENUE ANALYSIS
    • 21.15.3 PRODUCT PORTFOLIO
    • 21.15.4 RECENT DEVELOPMENTS
  • 21.16 ILLUMINA, INC.
    • 21.16.1 COMPANY SNAPSHOT
    • 21.16.2 REVENUE ANALYSIS
    • 21.16.3 PRODUCT PORTFOLIO
    • 21.16.4 RECENT DEVELOPMENTS
  • 21.17 LUPIN
    • 21.17.1 COMPANY SNAPSHOT
    • 21.17.2 REVENUE ANALYSIS
    • 21.17.3 PRODUCT PORTFOLIO
    • 21.17.4 RECENT DEVELOPMENTS
  • 21.18 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
    • 21.18.1 COMPANY SNAPSHOT
    • 21.18.2 REVENUE ANALYSIS
    • 21.18.3 PRODUCT PORTFOLIO
    • 21.18.4 RECENT DEVELOPMENTS
  • 21.19 PFIZER INC.
    • 21.19.1 COMPANY SNAPSHOT
    • 21.19.2 REVENUE ANALYSIS
    • 21.19.3 PRODUCT PORTFOLIO
    • 21.19.4 RECENT DEVELOPMENTS
  • 21.20 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 21.20.1 COMPANY SNAPSHOT
    • 21.20.2 REVENUE ANALYSIS
    • 21.20.3 PRODUCT PORTFOLIO
    • 21.20.4 RECENT DEVELOPMENTS
  • 21.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 21.21.1 COMPANY SNAPSHOT
    • 21.21.2 REVENUE ANALYSIS
    • 21.21.3 PRODUCT PORTFOLIO
    • 21.21.4 RECENT DEVELOPMENTS

22 QUESTIONNAIRE

23 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 GLOBAL NEUROENDOCRINE TUMORS MARKET, PIPELINE ANALYSIS
  • TABLE 2 SALES DATA OF ONCOLOGY MARKET FOR 2019/2020
  • TABLE 3 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2028(USD MILLION)
  • TABLE 4 GLOBAL NON-FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
  • TABLE 5 GLOBAL FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
  • TABLE 6 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
  • TABLE 7 GLOBAL GASTROINTESTINAL TRACT (GI) IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
  • TABLE 8 GLOBAL LUNGS IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
  • TABLE 9 GLOBAL PANCREAS NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
  • TABLE 10 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
  • TABLE 11 GLOBAL GRADE 2 (INTERMEDIATE-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
  • TABLE 12 GLOBAL GRADE 3 (HIGH-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
  • TABLE 13 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
  • TABLE 14 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 15 GLOBAL DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 16 GLOBAL DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 17 GLOBAL IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 18 GLOBAL TREATMENT NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 19 GLOBAL TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 20 GLOBAL SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 21 GLOBAL TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 22 GLOBAL RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 23 GLOBAL SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 24 GLOBAL LIVER-DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
  • TABLE 25 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 26 GLOBAL ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 27 GLOBAL ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 28 GLOBAL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 29 GLOBAL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 30 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 31 GLOBAL HOSPITALS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 32 GLOBAL SPECIALITY CLINICS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 33 GLOBAL RADIATION CENTERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 34 GLOBAL OTHERS IN RADIOTHERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 35 GLOBAL OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 36 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 37 GLOBAL DIRECT TENDER IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 38 GLOBAL HOSPITAL PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 39 GLOBAL RETAIL SALES IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 40 GLOBAL ONLINE PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 41 GLOBAL OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 42 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 43 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 44 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 45 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 46 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 47 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 48 NORTH AMERICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 49 NORTH AMERICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 50 NORTH AMERICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 51 NORTH AMERICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 52 NORTH AMERICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 53 NORTH AMERICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 54 NORTH AMERICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 55 NORTH AMERICA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 56 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 57 NORTH AMERICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 58 NORTH AMERICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 59 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 60 NORTH AMERICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 61 U.S. NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 62 U.S. NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 63 U.S. NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 64 U.S. NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 65 U.S. DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 66 U.S. IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 67 U.S. TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 68 U.S. SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 69 U.S. TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 70 U.S. RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 71 U.S. SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 72 U.S. LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 73 U.S. NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 74 U.S. ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 75 U.S. PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 76 U.S. NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 77 U.S. PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 78 CANADA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 79 CANADANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 80 CANADA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 81 CANADA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 82 CANADADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 83 CANADAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 84 CANADATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 85 CANADASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 86 CANADATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 87 CANADARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 88 CANADASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 89 CANADALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 90 CANADANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 91 CANADAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 92 CANADAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 93 CANADANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 94 CANADAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 95 MEXICONEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 96 MEXICO NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 97 MEXICO NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 98 MEXICO NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 99 MEXICO DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 100 MEXICO IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 101 MEXICO TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 102 MEXICO SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 103 MEXICO TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 104 MEXICO RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 105 MEXICO SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 106 MEXICOLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 107 MEXICONEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 108 MEXICOORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 109 MEXICOPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 110 MEXICONEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 111 MEXICO NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 112 EUROPE NEUROENDOCRINE TUMORS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
  • TABLE 113 EUROPENEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 114 EUROPENEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 115 EUROPENEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 116 EUROPENEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 117 EUROPEDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 118 EUROPEIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 119 EUROPETREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 120 EUROPESOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 121 EUROPETARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 122 EUROPERADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 123 EUROPESURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 124 EUROPELIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 125 EUROPENEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 126 EUROPEORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 127 EUROPEPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 128 EUROPENEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 129 EUROPE NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 130 GERMANY NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 131 GERMANY NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 132 GERMANY NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 133 GERMANYNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 134 GERMANYDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 135 GERMANY IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 136 GERMANY TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 137 GERMANY SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 138 GERMANY TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 139 GERMANY RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 140 GERMANY SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 141 GERMANYLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 142 GERMANYNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 143 GERMANYORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 144 GERMANYPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 145 GERMANYNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 146 GERMANY NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 147 FRANCE NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 148 FRANCE NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 149 FRANCE NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 150 FRANCE NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 151 FRANCE DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 152 FRANCE IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 153 FRANCETREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 154 FRANCESOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 155 FRANCETARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 156 FRANCERADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 157 FRANCESURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 158 FRANCELIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 159 FRANCENEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 160 FRANCEORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 161 FRANCEPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 162 FRANCENEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 163 FRANCE NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 164 U.K. NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 165 U.K. NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 166 U.K. NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 167 U.K. NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 168 U.K. DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 169 U.K. IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 170 U.K.TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 171 U.K.SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 172 U.K.TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 173 U.K.RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 174 U.K.SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 175 U.K.LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 176 U.K.NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 177 U.K.ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 178 U.K.PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 179 U.K.NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 180 U.K. NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 181 ITALYNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 182 ITALYNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 183 ITALYNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 184 ITALYNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 185 ITALYDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 186 ITALYIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 187 ITALYTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 188 ITALYSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 189 ITALYTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 190 ITALYRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 191 ITALYSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 192 ITALYLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 193 ITALYNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 194 ITALYORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 195 ITALYPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 196 ITALYNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 197 ITALY NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 198 RUSSIA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 199 RUSSIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 200 RUSSIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 201 RUSSIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 202 RUSSIADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 203 RUSSIAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 204 RUSSIATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 205 RUSSIASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 206 RUSSIATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 207 RUSSIARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 208 RUSSIASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 209 RUSSIALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 210 RUSSIANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 211 RUSSIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 212 RUSSIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 213 RUSSIANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 214 RUSSIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 215 SPAIN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 216 SPAIN NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 217 SPAIN NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 218 SPAIN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 219 SPAINDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 220 SPAINIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 221 SPAINTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 222 SPAINSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 223 SPAINTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 224 SPAINRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 225 SPAINSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 226 SPAINLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 227 SPAIN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 228 SPAINORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 229 SPAINPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 230 SPAIN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 231 SPAIN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 232 SWITZERLAND NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 233 SWITZERLAND NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 234 SWITZERLANDNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 235 SWITZERLANDNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 236 SWITZERLANDDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 237 SWITZERLANDIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 238 SWITZERLANDTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 239 SWITZERLANDSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 240 SWITZERLANDTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 241 SWITZERLANDRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 242 SWITZERLANDSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 243 SWITZERLANDLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 244 SWITZERLANDNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 245 SWITZERLANDORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 246 SWITZERLANDPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 247 SWITZERLANDNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 248 SWITZERLAND NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 249 NETHERLANDS NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 250 NETHERLANDS NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 251 NETHERLANDS NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 252 NETHERLANDS NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 253 NETHERLANDS DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 254 NETHERLANDS IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 255 NETHERLANDS TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 256 NETHERLANDS SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 257 NETHERLANDS TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 258 NETHERLANDS RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 259 NETHERLANDS SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 260 NETHERLANDS LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 261 NETHERLANDS NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 262 NETHERLANDS ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 263 NETHERLANDS PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 264 NETHERLANDS NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 265 NETHERLANDS NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 266 TURKEY NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 267 TURKEY NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 268 TURKEY NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 269 TURKEY NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 270 TURKEY DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 271 TURKEY IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 272 TURKEY TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 273 TURKEY SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 274 TURKEY TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 275 TURKEY RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 276 TURKEY SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 277 TURKEY LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 278 TURKEY NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 279 TURKEY ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 280 TURKEY PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 281 TURKEY NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 282 TURKEY NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 283 IRELANDNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 284 IRELANDNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 285 IRELANDNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 286 IRELANDNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 287 IRELANDDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 288 IRELANDIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 289 IRELANDTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 290 IRELANDSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 291 IRELANDTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 292 IRELANDRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 293 IRELANDSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 294 IRELANDLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 295 IRELANDNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 296 IRELANDORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 297 IRELANDPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 298 IRELANDNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 299 IRELAND NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 300 POLANDNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 301 POLANDNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 302 POLANDNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 303 POLANDNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 304 POLANDDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 305 POLANDIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 306 POLANDTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 307 POLANDSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 308 POLANDTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 309 POLANDRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 310 POLANDSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 311 POLANDLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 312 POLANDNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 313 POLANDORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 314 POLANDPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 315 POLANDNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 316 POLAND NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 317 AUSTRIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 318 AUSTRIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 319 AUSTRIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 320 AUSTRIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 321 AUSTRIADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 322 AUSTRIAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 323 AUSTRIATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 324 AUSTRIASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 325 AUSTRIATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 326 AUSTRIARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 327 AUSTRIASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 328 AUSTRIALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 329 AUSTRIANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 330 AUSTRIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 331 AUSTRIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 332 AUSTRIANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 333 AUSTRIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 334 NORWAYNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 335 NORWAYNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 336 NORWAYNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 337 NORWAYNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 338 NORWAYDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 339 NORWAYIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 340 NORWAYTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 341 NORWAYSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 342 NORWAYTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 343 NORWAYRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 344 NORWAYSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 345 NORWAYLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 346 NORWAYNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 347 NORWAYORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 348 NORWAYPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 349 NORWAYNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 350 NORWAY NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 351 HUNGARYNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 352 HUNGARYNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 353 HUNGARYNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 354 HUNGARYNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 355 HUNGARYDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 356 HUNGARYIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 357 HUNGARYTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 358 HUNGARYSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 359 HUNGARYTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 360 HUNGARYRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 361 HUNGARYSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 362 HUNGARYLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 363 HUNGARYNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 364 HUNGARYORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 365 HUNGARYPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 366 HUNGARYNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 367 HUNGARY NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 368 LITHUANIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 369 LITHUANIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 370 LITHUANIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 371 LITHUANIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 372 LITHUANIADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 373 LITHUANIAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 374 LITHUANIATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 375 LITHUANIASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 376 LITHUANIATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 377 LITHUANIARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 378 LITHUANIASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 379 LITHUANIALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 380 LITHUANIANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 381 LITHUANIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 382 LITHUANIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 383 LITHUANIANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 384 LITHUANIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 385 REST OF EUROPE NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2028 (USD MILLION)
  • TABLE 386 LITHUANIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 387 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
  • TABLE 388 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 389 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 390 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 391 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 392 ASIA PACIFICDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 393 ASIA PACIFICIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 394 ASIA PACIFICTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 395 ASIA PACIFICSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 396 ASIA PACIFICTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 397 ASIA PACIFICRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 398 ASIA PACIFICSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 399 ASIA PACIFICLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 400 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 401 ASIA PACIFICORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 402 ASIA PACIFICPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 403 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 404 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 405 CHINANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 406 CHINANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 407 CHINANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 408 CHINANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 409 CHINADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 410 CHINAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 411 CHINATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 412 CHINASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 413 CHINATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 414 CHINARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 415 CHINASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 416 CHINALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 417 CHINANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 418 CHINAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 419 CHINAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 420 CHINANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 421 CHINA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 422 JAPANNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 423 JAPANNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 424 JAPANNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 425 JAPANNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 426 JAPANDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 427 JAPANIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 428 JAPANTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 429 JAPANSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 430 JAPANTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 431 JAPANRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 432 JAPANSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 433 JAPANLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 434 JAPANNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 435 JAPANORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 436 JAPANPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 437 JAPANNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 438 JAPAN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 439 INDIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 440 INDIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 441 INDIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 442 INDIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 443 INDIADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 444 INDIAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 445 INDIATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 446 INDIASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 447 INDIATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 448 INDIARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 449 INDIASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 450 INDIALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 451 INDIANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 452 INDIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 453 INDIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 454 INDIANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 455 INDIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 456 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 457 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 458 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 459 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 460 AUSTRALIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 461 AUSTRALIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 462 AUSTRALIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 463 AUSTRALIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 464 AUSTRALIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 465 AUSTRALIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 466 AUSTRALIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 467 AUSTRALIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 468 AUSTRALIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 469 AUSTRALIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 470 AUSTRALIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 471 AUSTRALIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 472 AUSTRALIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 473 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 474 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 475 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 476 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 477 MALAYSIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 478 MALAYSIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 479 MALAYSIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 480 MALAYSIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 481 MALAYSIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 482 MALAYSIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 483 MALAYSIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 484 MALAYSIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 485 MALAYSIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 486 MALAYSIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 487 MALAYSIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 488 MALAYSIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 489 MALAYSIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 490 INDONESIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 491 INDONESIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 492 INDONESIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 493 INDONESIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 494 INDONESIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 495 INDONESIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 496 INDONESIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 497 INDONESIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 498 INDONESIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 499 INDONESIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 500 INDONESIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 501 INDONESIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 502 INDONESIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 503 INDONESIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 504 INDONESIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 505 INDONESIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 506 INDONESIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 507 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 508 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 509 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 510 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 511 SOUTH KOREA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 512 SOUTH KOREA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 513 SOUTH KOREA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 514 SOUTH KOREA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 515 SOUTH KOREA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 516 SOUTH KOREA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 517 SOUTH KOREA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 518 SOUTH KOREA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 519 SOUTH KOREAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 520 SOUTH KOREAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 521 SOUTH KOREAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 522 SOUTH KOREAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 523 SOUTH KOREA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 524 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 525 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 526 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 527 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 528 SINGAPORE DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 529 SINGAPORE IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 530 SINGAPORE TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 531 SINGAPORE SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 532 SINGAPORE TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 533 SINGAPORE RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 534 SINGAPORE SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 535 SINGAPORE LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 536 SINGAPOREEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 537 SINGAPOREORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 538 SINGAPOREPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 539 SINGAPOREEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 540 SINGAPORE NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 541 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 542 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 543 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 544 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 545 PHILIPPINESS DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 546 PHILIPPINESS IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 547 PHILIPPINESS TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 548 PHILIPPINESS SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 549 PHILIPPINESS TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 550 PHILIPPINESS RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 551 PHILIPPINESS SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 552 PHILIPPINESS LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 553 PHILIPPINESSEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 554 PHILIPPINESSORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 555 PHILIPPINESSPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 556 PHILIPPINESSEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 557 PHILIPPINESS NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 558 THAILAND NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 559 THAILANDNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 560 THAILANDNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 561 THAILANDNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 562 THAILAND DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 563 THAILAND IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 564 THAILAND TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 565 THAILAND SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 566 THAILAND TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 567 THAILAND RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 568 THAILAND SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 569 THAILAND LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 570 THAILANDEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 571 THAILANDORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 572 THAILANDPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 573 THAILANDEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 574 THAILAND NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 575 VIETNAM NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 576 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 577 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 578 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 579 VIETNAM DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 580 VIETNAM IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 581 VIETNAM TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 582 VIETNAM SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 583 VIETNAM TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 584 VIETNAM RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 585 VIETNAM SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 586 VIETNAM LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 587 VIETNAMEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 588 VIETNAMORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 589 VIETNAMPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 590 VIETNAMEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 591 VIETNAM NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 592 REST OF ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 593 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET, COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 594 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 595 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 596 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 597 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 598 SOUTH AMERICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 599 SOUTH AMERICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 600 SOUTH AMERICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 601 SOUTH AMERICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 602 SOUTH AMERICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 603 SOUTH AMERICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 604 SOUTH AMERICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 605 SOUTH AMERICA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 606 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 607 SOUTH AMERICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 608 SOUTH AMERICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 609 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 610 SOUTH AMERICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 611 BRAZIL NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 612 BRAZIL NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 613 BRAZIL NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 614 BRAZIL NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 615 BRAZIL DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 616 BRAZIL IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 617 BRAZIL TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 618 BRAZIL SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 619 BRAZIL TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 620 BRAZIL RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 621 BRAZIL SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 622 BRAZIL LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 623 BRAZIL NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 624 BRAZIL ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 625 BRAZIL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 626 BRAZIL NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 627 BRAZIL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 628 ARGENTINA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 629 ARGENTINA EUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 630 ARGENTINA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 631 ARGENTINA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 632 ARGENTINA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 633 ARGENTINA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 634 ARGENTINA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 635 ARGENTINA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 636 ARGENTINA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 637 ARGENTINA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 638 ARGENTINA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 639 ARGENTINA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 640 ARGENTINA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 641 ARGENTINA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 642 ARGENTINA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 643 ARGENTINA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 644 ARGENTINA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 645 PERU NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 646 PERU NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 647 PERU NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 648 PERU NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 649 PERU DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 650 PERU IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 651 PERU TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 652 PERU SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 653 PERU TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 654 PERU RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 655 PERU SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 656 PERU LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 657 PERU NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 658 PERU ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 659 PERU PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 660 PERU NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 661 PERU PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 662 REST OF SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 663 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 664 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 665 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 666 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 667 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 668 MIDDLE EAST AND AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
  • TABLE 669 MIDDLE EAST AND AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 670 MIDDLE EAST AND AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 671 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 672 MIDDLE EAST AND AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 673 MIDDLE EAST AND AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 674 MIDDLE EAST AND AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 675 MIDDLE EAST AND AFRICA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 676 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
  • TABLE 677 MIDDLE EAST ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 678 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 679 MIDDLE EASTA AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 680 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 681 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
  • TABLE 682 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 683 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 684 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 685 SOUTH AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 686 SOUTH AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 687 SOUTH AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 688 SOUTH AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 689 SOUTH AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 690 SOUTH AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 691 SOUTH AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 692 SOUTH AFRICA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 693 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 694 SOUTH AFRICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 695 SOUTH AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 696 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 697 SOUTH AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 698 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 699 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 700 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 701 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 702 SAUDI ARABIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 703 SAUDI ARABIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 704 SAUDI ARABIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 705 SAUDI ARABIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 706 SAUDI ARABIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 707 SAUDI ARABIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 708 SAUDI ARABIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 709 SAUDI ARABIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 710 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 711 SAUDI ARABIA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 712 SAUDI ARABIA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 713 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 714 SAUDI ARABIA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 715 EGYPT EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 716 EGYPT NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 717 EGYPT NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 718 EGYPT NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 719 EGYPT DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 720 EGYPT IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 721 EGYPT TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 722 EGYPT SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 723 EGYPT TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 724 EGYPT RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 725 EGYPT SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 726 EGYPT LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 727 EGYPT NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 728 EGYPT ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 729 EGYPT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 730 EGYPT NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 731 EGYPT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 732 ISRAEL EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 733 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 734 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 735 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 736 ISRAEL DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 737 ISRAEL IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 738 ISRAEL TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 739 ISRAEL SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 740 ISRAEL TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 741 ISRAEL RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 742 ISRAEL SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 743 ISRAEL LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 744 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 745 ISRAEL ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 746 ISRAEL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 747 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 748 ISRAEL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 749 UAE EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 750 UAE NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 751 UAE NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 752 UAE NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 753 UAE DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 754 UAE IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 755 UAE TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 756 UAE SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 757 UAE TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 758 UAE RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 759 UAE SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 760 UAE LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 761 UAE NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 762 UAE ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 763 UAE PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 764 UAE NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 765 UAE PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 766 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
  • TABLE 767 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
  • TABLE 768 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
  • TABLE 769 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 770 KUWAIT DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 771 KUWAIT IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 772 KUWAIT TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 773 KUWAIT SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 774 KUWAIT TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 775 KUWAIT RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 776 KUWAIT SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 777 KUWAIT LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 778 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 779 KUWAIT ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 780 KUWAIT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • TABLE 781 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 782 KUWAIT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 783 REST OF MIDDLE EAST AND AFRICA EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL NEUROENDOCRINE TUMORS MARKET: SEGMENTATION 59
  • FIGURE 2 GLOBAL NEUROENDOCRINE TUMORS MARKET: DATA TRIANGULATION 62
  • FIGURE 3 GLOBAL NEUROENDOCRINE TUMORS MARKET: DROC ANALYSIS 63
  • FIGURE 4 GLOBAL NEUROENDOCRINE TUMORS MARKET: GLOBAL VS REGIONAL ANALYSIS 64
  • FIGURE 5 GLOBAL NEUROENDOCRINE TUMORS MARKET: COMPANY RESEARCH ANALYSIS 64
  • FIGURE 6 GLOBAL NEUROENDOCRINE TUMORS MARKET: INTERVIEW DEMOGRAPHICS 65
  • FIGURE 7 GLOBAL NEUROENDOCRINE TUMORS MARKET: DBMR MARKET POSITION GRID 67
  • FIGURE 8 GLOBAL NEUROENDOCRINE TUMORS MARKET: VENDOR SHARE ANALYSIS 68
  • FIGURE 9 GLOBAL NEUROENDOCRINE TUMORS MARKET: MARKET END USER COVERAGE GRID 69
  • FIGURE 10 GLOBAL NEUROENDOCRINE TUMORS MARKET: SEGMENTATION 73
  • FIGURE 11 INCREASED INCIDENCE OF NEUROENDOCRINE TUMORS CASES IS EXPECTED TO DRIVE THE GLOBAL NEUROENDOCRINE TUMORS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 74
  • FIGURE 12 NON-FUNTIONAL NET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL NEUROENDOCRINE TUMORS MARKET IN 2021 & 2028 74
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL NEUROENDOCRINE TUMORS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028 75
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR NEUROENDOCRINE TUMORS MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028 76
  • FIGURE 15 FIVE YEAR SURVIVAL RATE OF PANCREATIC NEUROENDOCRINE TUMOR BETWEEN 2010- 2016 85
  • FIGURE 16 INCIDENCE OF NEO-ENDOCRINE NEOPLASM IN CHINA, EUROPE AND U.S. 86
  • FIGURE 17 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, 2020 97
  • FIGURE 18 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2020-2028 (USD MILLION) 99
  • FIGURE 19 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, CAGR (2021-2028) 99
  • FIGURE 20 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, LIFELINE CURVE 100
  • FIGURE 21 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY SITE, 2020 104
  • FIGURE 22 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY SITE, 2020-2028 (USD MILLION) 105
  • FIGURE 23 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY SITE, CAGR (2021-2028) 105
  • FIGURE 24 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY SITE, LIFELINE CURVE 106
  • FIGURE 25 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY GRADE, 2020 111
  • FIGURE 26 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2020-2028 (USD MILLION) 112
  • FIGURE 27 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY GRADE, CAGR (2021-2028) 112
  • FIGURE 28 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY GRADE, LIFELINE CURVE 113
  • FIGURE 29 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY TYPE, 2020 117
  • FIGURE 30 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2020-2028 (USD MILLION) 118
  • FIGURE 31 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY TYPE, CAGR (2021-2028) 118
  • FIGURE 32 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY TYPE, LIFELINE CURVE 119
  • FIGURE 33 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, 2020 127
  • FIGURE 34 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION) 129
  • FIGURE 35 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028) 129
  • FIGURE 36 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINSTRATION, LIFELINE CURVE 130
  • FIGURE 37 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY END USER, 2020 135
  • FIGURE 38 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY END USER, 2020-2028 (USD MILLION) 136
  • FIGURE 39 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY END USER, CAGR (2021-2028) 136
  • FIGURE 40 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY END USER, LIFELINE CURVE 137
  • FIGURE 41 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, 2020 143
  • FIGURE 42 GLOBAL NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION) 144
  • FIGURE 43 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028) 144
  • FIGURE 44 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 145
  • FIGURE 45 GLOBAL NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020) 152
  • FIGURE 46 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY REGION (2020) 154
  • FIGURE 47 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY REGION (2020 & 2028) 154
  • FIGURE 48 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY REGION (2020 & 2028) 155
  • FIGURE 49 GLOBAL NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION (2021-2028) 155
  • FIGURE 50 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020) 157
  • FIGURE 51 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2020) 159
  • FIGURE 52 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028) 159
  • FIGURE 53 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028) 160
  • FIGURE 54 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION (2021-2028) 160
  • FIGURE 55 EUROPE NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020) 181
  • FIGURE 56 EUROPE NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2020) 183
  • FIGURE 57 EUROPE NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028) 183
  • FIGURE 58 EUROPE NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028) 184
  • FIGURE 59 EUROPE NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION (2021-2028) 184
  • FIGURE 60 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020) 251
  • FIGURE 61 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2020) 253
  • FIGURE 62 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028) 253
  • FIGURE 63 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028) 254
  • FIGURE 64 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY STRAINS (2021-2028) 254
  • FIGURE 65 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020) 305
  • FIGURE 66 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2020) 307
  • FIGURE 67 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028) 307
  • FIGURE 68 SOUTH AMERICA AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028) 308
  • FIGURE 69 SOUTH AMERICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION (2021-2028) 308
  • FIGURE 70 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020) 326
  • FIGURE 71 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2020) 328
  • FIGURE 72 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028) 328
  • FIGURE 73 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028) 329
  • FIGURE 74 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION (2021-2028) 329
  • FIGURE 75 GLOBAL NEUROENDOCRINE TUMORS MARKET: COMPANY SHARE 2020 (%) 360
  • FIGURE 76 NORTH AMERICA NEUROENDOCRINE TUMORS MARKET: COMPANY SHARE 2020 (%) 361
  • FIGURE 77 EUROPE NEUROENDOCRINE TUMORS MARKET: COMPANY SHARE 2020 (%) 362
  • FIGURE 78 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY SHARE 2020 (%) 363